Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Aarti Pharmalabs Limited

NSE: AARTIPHARMPharmaceuticals

Share price

₹855.50

-2.68% close of 9 Oct 2026

Market cap ₹7,763 CrP/E 36.8 (as of 8 Oct 2026)

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 7 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

53

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹7,763 Cr

P/E ratio

36.8

P/B ratio

3.7

ROCE

10.7%

ROE

8.6%

Dividend yield

0.4%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹975.0052-week low ₹591.95

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 1.2% over the past year, and -0.0% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 17.5% to 21.6% over the last three years.

Whether it grew faster than its sector

It grew -0.0% a year against a sector median of 13.1% — 13.1 percentage points slower.

Room to re-rate, or risk of de-rating

At 36.8× earnings it costs 1.5× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 26.0×, the 99th percentile of its own range.

Whether growth justifies the valuation

Its earnings are falling, so growth cannot justify the price.

Profit growthPrice per ₹1 profitPer 1% growth
Aarti Pharmalabs Limited — this one-3%/yr36.8×—
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 86 of 130 on returns, 117 of 127 on growth, 56 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 10.7% on capital, ahead of 34% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

No — Over the last five years it made ₹1014 crore of cash from the business but spent ₹1351 crore on plant and equipment, ₹337 crore more than it made; the gap was mostly borrowed — borrowings rose from ₹338 crore to ₹754 crore. And the profit is real: of every 100 rupees it reported over 6 years, about 104 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back faster than it used to: it went from being waiting 111 days for its cash to waiting 90 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

7 of 9 checks clear · 78%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Record caffeine-ingredients quarter lifted sales 39%, but the new plant landed three months late.

Announced 7 Aug 2026 · Consolidated · Unaudited

Revenue

₹536 Cr

Revenue vs last year

+38.7%

Revenue vs last quarter

-8.0%

Net profit

₹76 Cr

Profit vs last year

+52.3%

Profit vs last quarter

+24.8%

Net margin

14.2%

EPS

₹8.40

Earnings call transcript · 10 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹7,763 Cr
Prev close
₹855.50
52w High
₹1,002
52w Low
₹585
Enterprise value
₹8,721 Cr
Beta
1.1
Price CAGR 1y
15.0%
Price CAGR 3y
31.0%
Price CAGR 5y
—
Price CAGR 10y
—

Ratios

Return on assets
5.0%
PEG ratio
-12.0
P/E ratio
36.8
P/B ratio
3.7
EV / EBITDA
23.7
Industry P/E
37.6
ROCE
10.7%
ROCE 5y average
16.0%
ROE
8.6%
Debt / Equity
0.4
Interest coverage
6.0
Dividend yield
0.4%
ROE 3y average
12.0%
ROE last year
9.0%

Annual P&L

Annual revenue
₹1,819 Cr
Annual profit
₹175 Cr
Operating margin
20.0%
Net profit margin
9.6%
EBITDA margin
20.3%
Sales growth 3y
-2.2%
Sales growth 5y
—
Profit growth 3y
-3.0%
Profit growth 5y
—
EPS
₹19.3
Sales growth TTM
1.0%
Profit growth TTM
-19.0%
Dividend payout
18.0%

Quarter P&L

Sales latest quarter
₹536 Cr
Profit latest quarter
₹76 Cr
YoY quarterly sales growth
38.7%
YoY quarterly profit growth
52.0%
OPM latest quarter
25.4%

Balance Sheet

Book Value
₹236
Face Value
₹5.0
Total debt
₹754 Cr
Total cash
₹10 Cr
Borrowings
₹754 Cr
Reserves / Equity
46.2

Cash Flow

Operating cash flow
₹262 Cr
Free cash flow
-₹186 Cr
FCF yield
-3.0%
Net cash flow
₹2 Cr

Shareholding

Promoter holding
42.9%
FII holding
8.2%
DII holding
7.2%
Public holding
41.7%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.94,28,0570.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.52,54,6650.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.31,79,1640.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,14,9630.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.31,10,6990.10362.1125.52,026.329.117.8
Cipla1,327.2029.91,06,9970.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.71,03,8760.04574.129.64,030.612.913.5
Aarti Pharma953.3540.28,6480.3776.153.8535.838.710.7
Median417.9034.42,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales458440449506555458538564386418432583536
Expenses373352353388459364409418293344330470400
Material Cost191203209226252
Change in Inventories-44-17-3949-43
Purchases of Stock-in-Trade22232.148.7327
Employee Cost4143434550
Other Expenses8090114141113
Operating Profit85889611896941291469374102113136
OPM %19202123172024262418241925
Other Income0112245-2202148
Exceptional items (within Other Income)00-2.7900
Interest444556107711131713
Depreciation17181919202123232325292830
Profit before tax64677496747210111565396382101
Tax %26232932252426232428242525
Net Profit47525365555574885028486176
EPS in Rs5.205.725.827.206.126.038.169.755.463.085.296.748.40
Diluted EPS in Rs5.463.085.296.748.39

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales01,2001,9451,8532,1151,8191,969
Expenses09931,6031,4671,6491,4501,543
Material Cost830
Change in Inventories-51
Purchases of Stock-in-Trade56
Employee Cost173
Other Expenses442
Operating Profit0207342386466369426
OPM %171821222022
Other Income032581523
Exceptional items (within Other Income)-2.79
Interest0122117274753
Depreciation042637387104112
Profit before tax0155261300361233284
Tax %2126282425
Net Profit0122193217272175213
EPS in Rs2124301924
Diluted EPS in Rs19
Dividend Payout %09131718

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
—
5 years
—
3 years
-2%
TTM
1%

Compounded profit growth

10 years
—
5 years
—
3 years
-3%
TTM
-19%

Stock price CAGR

10 years
—
5 years
—
3 years
31%
1 year
15%

Return on equity

10 years
—
5 years
13%
3 years
12%
Last year
9%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital0.250.2545454545
Reserves-01,3861,5131,7121,9452,079
Borrowings0338215285413754
Other Liabilities0315470540499603
Total Liabilities02,0402,2442,5822,9023,482
Fixed Assets07829261,0331,1371,437
CWIP0187102137374393
Investments0328710777194
Other Assets01,0381,1301,3051,3151,457
Total Assets02,0402,2442,5822,9023,482

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity0-44250216330262
Cash from Investing Activity0-139-158-215-412-431
Cash from Financing Activity0260-1631065171
Net Cash Flow078-7112-172
Free Cash Flow0-18513018-114-186

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1158410299117
Inventory Days272188230199280
Days Payable12310613594146
Cash Conversion Cycle264166197204251
Working Capital Days1119411010590
ROCE %1916171711

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters464646464645444443434343
FIIs8.458.178.337.077.388.647.367.348.027.698.398.17
DIIs119.919.971111107.537.806.957.667.407.22
Government0.010.010.010.010.010.010.010.010.010.010.010.01
Public353535353536414142424142
No. of Shareholders2,26,2862,15,7962,04,1221,89,0121,85,4361,85,1111,96,3141,87,0391,90,6551,84,4891,79,3731,76,506

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +2.5% (₹834.75 → ₹855.50)Brick size ₹47.74 (fixed)Bricks 17
₹600₹700₹800₹900₹856Jan '26May '26
Price moved up one brickPrice moved down one brickLast close ₹855.50 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

74,24,831inr

2026-03-31

News

News and filings about Aarti Pharmalabs Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • dimethyl sulphate
  • dimethyl urea
  • key starting materials & chemical intermediates for APIs and xanthine derivatives
  • solvents

Sells drug ingredients to

Sells to

  • Global innovator pharma & biotech (CDMO/CMO customers) · custom intermediates / APIs (CDMO/CMO)

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE0LRU01027

Plants

  • Aarti Pharmalabs Atali greenfield (multipurpose + CDMO)
  • Aarti Pharmalabs Tarapur Unit-III
  • Aarti Pharmalabs Tarapur Unit-IV (steroid block)
  • Aarti Pharmalabs Tarapur Unit-V
  • Aarti Pharmalabs Tarapur Unit-VI
  • Aarti Pharmalabs Unit-I Dombivli
  • Aarti Pharmalabs Unit-II Custom Synthesis Division

News impact

Big market events that reach Aarti Pharmalabs Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

15 Sep 2026unspecified₹2
16 Feb 2026interim₹1.5
15 Sep 2025unspecified₹2.5
14 Feb 2025interim₹2.5
31 Jul 2024unspecified₹1
16 Feb 2024interim₹2

Splits, bonuses & buybacks

  • daily-prices repair: 8 rows from NSE's archive (replace 2, delete 1, insert 5), 2023-11-12..2026-02-01 (docs/flat_day_repair.md)1× · 12 Nov 2023

Bulk & block deals

DateWhoBought / soldSharesPrice
21 Sep 2026UNIFI CAPITAL PRIVATE LIMITEDBUY9,15,000₹820.00
18 Sep 2026JASMINE FAMILY TRUSTSELL6,27,500₹820.02
11 Aug 2026MICROCURVES TRADING PRIVATE LIMITEDSELL7,17,028₹904.35
11 Aug 2026MICROCURVES TRADING PRIVATE LIMITEDBUY7,17,028₹903.94
11 Aug 2026NK SECURITIES RESEARCH PRIVATE LIMITEDSELL6,40,653₹903.73
11 Aug 2026NK SECURITIES RESEARCH PRIVATE LIMITEDBUY6,40,416₹903.39
11 Aug 2026QE SECURITIES LLPBUY5,76,747₹899.52
11 Aug 2026QE SECURITIES LLPSELL5,70,009₹902.18
11 Aug 2026JUNOMONETA FINSOL PRIVATE LIMITEDBUY4,57,940₹901.69
11 Aug 2026JUNOMONETA FINSOL PRIVATE LIMITEDSELL4,55,661₹902.03

Insider trades

DisclosedWhoTypeSharesValue ₹ Cr
25 Sep 2026Gloire Trusteeship Services Private Limited · Promoter GroupSELL3,97,50032.55
25 Sep 2026RAJENDRA VALLABHAJI GOGRI · PromoterSELL3,88,72531.83
25 Sep 2026Relacion Trusteeship Services Private Limited · PromoterSELL3,80,00031.12
25 Sep 2026ARTI RAJENDRA GOGRI · Promoter GroupSELL1,33,56410.94
22 Sep 2026Relacion Trusteeship Services Private Limited · Promoter GroupSELL6,27,50051.38
22 Sep 2026Gloire Trusteeship Services Private Limited · Promoter GroupSELL6,24,50051.14
9 Sep 2026Relacion Trusteeship Services Private Limited · Promoter GroupSELL60,0005.23
9 Sep 2026Safechem Enterprises Private Limited · Promoter GroupSELL59,4005.20
7 Sep 2026Safechem Enterprises Private Limited · Promoter GroupSELL30,0002.59
31 Aug 2026Safechem Enterprises Private Limited · Promoter GroupSELL6000.05

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.